Zoetis Inc. (NYSE:ZTS) Stake Boosted by Summit Trail Advisors LLC

Summit Trail Advisors LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 46.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,269 shares of the company’s stock after purchasing an additional 2,961 shares during the quarter. Summit Trail Advisors LLC’s holdings in Zoetis were worth $1,510,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Darwin Wealth Management LLC bought a new position in Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter worth approximately $33,000. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC grew its holdings in Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Morgan Stanley decreased their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Piper Sandler decreased their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $214.00.

Zoetis Price Performance

ZTS opened at $171.71 on Tuesday. The stock has a fifty day moving average of $169.26 and a 200-day moving average of $179.21. The firm has a market capitalization of $77.47 billion, a P/E ratio of 32.28, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. Zoetis’s payout ratio is currently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.